ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 992,87
0,18%
Dow Jones
38 686,32
1,51%
DAX
18 497,94
-0,09%
Brent Oil
81,295
0,00%
Bitcoin
67 630,73
0,22%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Tarsus Pharmaceuticals Inc (TARS)

  7. Tarsus Pharmaceuticals Inc (TARS) Actualités

TARS

Tarsus Pharmaceuticals (TARS)

Tarsus Pharmaceuticals Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:TARS
DateHeureSourceTitreSymboleSociété
29/05/202423h00GlobeNewswire Inc.Tarsus to Participate in Upcoming Investor ConferencesNASDAQ:TARSTarsus Pharmaceuticals Inc
09/05/202423h00GlobeNewswire Inc.Tarsus to Participate in Fireside Chat at the 2024 Bank of America Healthcare ConferenceNASDAQ:TARSTarsus Pharmaceuticals Inc
08/05/202422h12Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:TARSTarsus Pharmaceuticals Inc
08/05/202422h09Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:TARSTarsus Pharmaceuticals Inc
08/05/202422h05GlobeNewswire Inc.Tarsus Reports First Quarter 2024 Financial Results and Recent Business AchievementsNASDAQ:TARSTarsus Pharmaceuticals Inc
01/05/202423h00GlobeNewswire Inc.Tarsus to Report First Quarter 2024 Financial Results on Wednesday, May 8, 2024NASDAQ:TARSTarsus Pharmaceuticals Inc
23/04/202414h30GlobeNewswire Inc.Tarsus Strengthens Financial Position and Refinances Existing Debt with $200 Million Non-dilutive Financing Commitment from PharmakonNASDAQ:TARSTarsus Pharmaceuticals Inc
11/03/202422h57Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:TARSTarsus Pharmaceuticals Inc
05/03/202422h30GlobeNewswire Inc.Tarsus to Participate at Upcoming Investor ConferencesNASDAQ:TARSTarsus Pharmaceuticals Inc
05/03/202414h30GlobeNewswire Inc.Tarsus Introduces “Mite Party” Campaign for XDEMVY® (lotilaner ophthalmic solution) 0.25% to Educate Consumers about Demodex BlepharitisNASDAQ:TARSTarsus Pharmaceuticals Inc
01/03/202423h17Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:TARSTarsus Pharmaceuticals Inc
01/03/202406h07GlobeNewswire Inc.Tarsus Announces Pricing of $100.0 Million Public OfferingNASDAQ:TARSTarsus Pharmaceuticals Inc
29/02/202422h37GlobeNewswire Inc.Tarsus Announces Proposed $100.0 Million Public OfferingNASDAQ:TARSTarsus Pharmaceuticals Inc
29/02/202422h32Edgar (US Regulatory)Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuersNASDAQ:TARSTarsus Pharmaceuticals Inc
27/02/202422h22Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:TARSTarsus Pharmaceuticals Inc
27/02/202422h02Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:TARSTarsus Pharmaceuticals Inc
27/02/202412h00GlobeNewswire Inc.Tarsus Reports Strong Fourth Quarter and Full-Year 2023 Financial Results and Recent Business AchievementsNASDAQ:TARSTarsus Pharmaceuticals Inc
22/02/202414h00GlobeNewswire Inc.Tarsus Announces Positive Topline Results from Carpo, a Phase 2a Proof-of-Concept “Tick-Kill” Trial Evaluating TP-05 (lotilaner) for the Prevention of Lyme DiseaseNASDAQ:TARSTarsus Pharmaceuticals Inc
20/02/202423h00GlobeNewswire Inc.Tarsus to Report Fourth Quarter and Full Year 2023 Financial Results on Tuesday, February 27, 2024NASDAQ:TARSTarsus Pharmaceuticals Inc
31/01/202423h00GlobeNewswire Inc.Tarsus to Participate in Fireside Chat at the Sixth Annual Guggenheim Healthcare Talks ConferenceNASDAQ:TARSTarsus Pharmaceuticals Inc
22/01/202423h05Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:TARSTarsus Pharmaceuticals Inc
27/12/202322h23Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:TARSTarsus Pharmaceuticals Inc
11/12/202314h00GlobeNewswire Inc.Tarsus Announces Positive Topline Results from the Ersa Phase 2a Clinical Trial Evaluating TP-03 for the Treatment of Meibomian Gland Disease in Patients with Demodex MitesNASDAQ:TARSTarsus Pharmaceuticals Inc
22/11/202306h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:TARSTarsus Pharmaceuticals Inc
09/11/202322h18Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:TARSTarsus Pharmaceuticals Inc
09/11/202322h05GlobeNewswire Inc.Tarsus Reports Third Quarter 2023 Financial Results and Recent Business AchievementsNASDAQ:TARSTarsus Pharmaceuticals Inc
01/11/202323h35GlobeNewswire Inc.Tarsus to Report Third Quarter 2023 Financial Results on Thursday, November 9, 2023NASDAQ:TARSTarsus Pharmaceuticals Inc
06/09/202314h00GlobeNewswire Inc.Tarsus to Ring Nasdaq Stock Market Closing Bell in Celebration of the Launch of XDEMVY™, the First and Only FDA Approved Treatment for Demodex BlepharitisNASDAQ:TARSTarsus Pharmaceuticals Inc
30/08/202322h30GlobeNewswire Inc.Tarsus to Present at Upcoming Investor ConferencesNASDAQ:TARSTarsus Pharmaceuticals Inc
24/08/202315h00GlobeNewswire Inc.Now Available – XDEMVY™ (lotilaner ophthalmic solution) 0.25%, the First and Only FDA Approved Treatment for Demodex BlepharitisNASDAQ:TARSTarsus Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:TARS

Dernières Valeurs Consultées

COIN
MCBGBP
LSE
06GM
Cambdge.wtr4%db
AMEX
FEEU
NASDAQ
FTCS
First Trust Capital Stre...
USOTC
PPHI
Positive Physicans (CE)
LSE
FM39
Barclays 27
NYSE
NBGR
Neuberger Berman
BIT
UC3T3P
Unicredit Bank
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés